Trial Data Show Extended Benefit With Inebilizumab in Myasthenia Gravis

Trial Data Show Extended Benefit With Inebilizumab in Myasthenia Gravis

(MedPage Today) -- Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting...

Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

The associate professor of neurology at Yale School of Medicine discussed 52-week data from the phase 3 MINT trial of inebilizumab in patients with generalized myasthenia gravis. [WATCH TIME: 5 minutes]